Does 1 Year Adjuvant Chemotherapy with Oral 5-FUs in Colon Cancer Reduce the Peak of Recurrence in 1 Year and Provide Long-term OS Benefit?

被引：9

作者：

Hamada, Chikuma ^{[1
]}

Sakamoto, Junichi ^{[2
]}

Satoh, Taroh ^{[3
]}

Sadahiro, Sotaro ^{[4
]}

Mishima, Hideyuki ^{[5
]}

Sugihara, Kenichi ^{[6
]}

Saji, Shigetoyo ^{[7
]}

Tomita, Naohiro ^{[8
]}

机构：

[1] Tokyo Univ Sci, Fac Engn, Shinjuku Ku, Tokyo 1628601, Japan

[2] Nagoya Univ, Grad Sch Med, Young Leaders Program, Nagoya, Aichi 4648601, Japan

[3] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan

[4] Tokai Univ, Kanagawa 2591100, Japan

[5] Osaka Natl Hosp, Osaka, Japan

[6] Tokyo Med & Dent Univ, Tokyo, Japan

[7] Japanese Fdn Multidisciplinary Treatment Canc, Tokyo, Japan

[8] Hyogo Coll Med, Dept Surg, Div Lower GI, Nishinomiya, Hyogo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 41卷 / 02期

关键词：

adjuvant chemotherapy; colon cancer; oral; 5-fluorouracil; hazard function; COLORECTAL-CANCER;

D O I：

10.1093/jjco/hyq209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The objective of our study was to clarify the characteristics of survival and hazard function in patients who received adjuvant chemotherapy after surgery for colon cancer. The data of 2848 patients with curatively resected colon cancer were analyzed; we used the patient data provided by the Japanese Foundation for Multidisciplinary Treatment for Cancer in three trials, namely, JFMC7-1 (n = 869), JFMC7-2 (n = 978) and JFMC15 (n = 1001). The total number of events were 605 (overall survival) and 724 (disease-free survival). The disease-free survival events consisted of 117 cases of death and 607 cases of disease recurrences. Logrank test showed a borderline significant difference in both overall survival (P = 0.0452) and disease-free survival (P = 0.0462). The 5 year overall survival proportion was 0.769 (control) and 0.802 (treated), and the absolute drug effect was 3.3%. The difference between the 5 year disease-free survival proportion (0.728 [control] and 0.760 [drug]) was 3.2%, which is almost similar to the result of overall survival. The disease-free survival curve of the treated group differed from that of the control group after 1 year, whereas the overall survival curve of the treated group became distinct from that of the control group after 2 years. The hazard rate plots indicated the possibility that 1 year adjuvant chemotherapy with oral 5-fluorouracils may translate the short-term reduction in the risk of recurrence in patients with resected colon cancer into a delayed advantage in overall survival.

引用

页码：299 / 302

页数：4

共 11 条

[1] A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer [J].

Chau, I ;

Norman, AR ;

Cunningham, D ;

Tait, D ;

Ross, PJ ;

Iveson, T ;

Hill, M ;

Hickish, T ;

Lofts, F ;

Jodrell, D ;

Webb, A ;

Oates, JR .

ANNALS OF ONCOLOGY, 2005, 16 (04) :549-557

[2]

DESGUETZ G, 2010, COCHRANE DB SYST REV, V20, P7046

[3]

*JAP FDN MULT TREA, 1996, 7 JAP FDN MULT TREAT

[4]

*JAP FDN MULT TREA, 1999, 15 JAP FDN MULT TREA

[5] Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials [J].

Sakamoto J. .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :484-492

[6] HAZARD RATE ESTIMATION UNDER RANDOM CENSORING WITH VARYING KERNELS AND BANDWIDTHS [J].

MULLER, HG ;

WANG, JL .

BIOMETRICS, 1994, 50 (01) :61-76

[7]

Nakamura T, 2001, INT J ONCOL, V19, P291

[8] Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J].

Sakuramoto, Shinichi ;

Sasako, Mitsuru ;

Yamaguchi, Toshiharu ;

Kinoshita, Taira ;

Fujii, Masashi ;

Nashimoto, Atsushi ;

Furukawa, Hiroshi ;

Nakajima, Toshifusa ;

Ohashi, Yasuo ;

Imamura, Hiroshi ;

Higashino, Masayuki ;

Yamamura, Yoshitaka ;

Kurita, Akira ;

Arai, Kuniyoshi .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (18) :1810-1820

[9] Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials [J].

Sargent, Daniel ;

Sobrero, Alberto ;

Grothey, Axel ;

O'Connell, Michael J. ;

Buyse, Marc ;

Andre, Thierry ;

Zheng, Yan ;

Green, Erin ;

Labianca, Roberto ;

O'Callaghan, Chris ;

Seitz, Jean Francois ;

Francini, Guido ;

Haller, Daniel ;

Yothers, Greg ;

Goldberg, Richard ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) :872-877

[10]

TWELVES C, 2005, NEW ENGL J MED, V352, P2746

← 1 2 →